NICE demands more data for Sanofi's oral MS drug Aubagio
Posted: Wed Sep 18, 2013 12:21 am
Sanofi will need to provide more evidence supporting the effectiveness of its oral multiple sclerosis drug Aubagio if it wants the treatment to be recommended for use on the NHS in England and Wales.
The National Institute for Health and Care Excellence (NICE), which assesses the cost-effectiveness of treatments for NHS use, released initial draft guidance which requests several clarifications on the evidence submitted by Sanofi, which is looking to market Aubagio (teriflunomide) as a first-line treatment for relapsing remitting multiple sclerosis (RRMS)....... Read More - http://www.ms-uk.org/aubagio
The National Institute for Health and Care Excellence (NICE), which assesses the cost-effectiveness of treatments for NHS use, released initial draft guidance which requests several clarifications on the evidence submitted by Sanofi, which is looking to market Aubagio (teriflunomide) as a first-line treatment for relapsing remitting multiple sclerosis (RRMS)....... Read More - http://www.ms-uk.org/aubagio